A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Conditions
Hepatorenal Syndrome Type 1
What is the purpose of this trial?
This study is designed to evaluate the efficacy and safety of intravenous Lucassin® (terlipressin) versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in subjects receiving standard of care albumin therapy.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Ikaria Holdings Inc.
- Dates:
- September 2010
- Last Updated:
- June 7, 2012
- Study HIC#:
- 1009007343
Clinicaltrials.gov ID: NCT01143246
For more information about this trial, contact:
Danielle Jacques
203-785-7031
Danielle.lettieri@yale.edu
Investigator
Sukru Emre, MD
Principal Investigator
